Evidence map›Paper›PMID 35935575›Full record

ArticleJournal of immunology research2022

SARS-CoV-2-Specific T Cell Immunity in HIV-Associated Kaposi Sarcoma Patients in Zambia.

Owen Ngalamika, Marie Claire Mukasine, Patrick Kamanzi, Musonda Kawimbe, Aaron Mujajati, For Yue Tso, Salum J Lidenge, Chibamba Mumba

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. The immune response to SARS-CoV-2 in people with HIV.Cellular & molecular immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Owen NgalamikaDermatology and Venereology Division, Adult University Teaching Hospital, University of Zambia School of Medicine, Lusaka, Zambia.ORCID https://orcid.org/0000-0002-0648-4128
Marie Claire MukasineHHV-8 Molecular Virology Laboratory, University Teaching Hospital, Lusaka, Zambia.
Patrick KamanziDermatology and Venereology Division, Adult University Teaching Hospital, University of Zambia School of Medicine, Lusaka, Zambia.
Musonda KawimbeHHV-8 Molecular Virology Laboratory, University Teaching Hospital, Lusaka, Zambia.
Aaron MujajatiCarepeak Specialist Clinic, Lusaka, Zambia.
For Yue TsoDepartment of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Salum J LidengeOcean Road Cancer Institute, Dar-es-Salam, Tanzania.ORCID https://orcid.org/0000-0002-0574-6595
Chibamba MumbaDepartment of Pathology and Microbiology, University of Zambia School of Medicine, Lusaka, Zambia.
University Teaching Hospital · ZMLouisiana State University Health Sciences Center New Orleans · USMuhimbili University of Health and Allied Sciences · TZUniversity of Zambia · ZM

Funding

Zambia AIDS Malignancies Diagnosis and Pathogenesis Program SupplementU54CA221204 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2017 to 2022
$3.8M
KSHV,HIV and the Kaposi's Sarcoma Tumor NicheR01CA228178 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WEST, JOHN T., WOOD, CHARLES · 2018 to 2024
$2.9M
AIDS Malignancies Training and Research International Program (AMTRIP)D43TW010354 · FIC · UNIVERSITY OF NEBRASKA LINCOLN · PI Chipepo Kankasa, Charles Wood · 2016 to 2026
$2.8M
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"K43TW011418 · FIC · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI LIDENGE, SALUM JUMA · 2019 to 2023
$741k
Biomarkers of Kaposi sarcoma recrudescence in ZambiaK43TW011095 · FIC · UNIVERSITY OF ZAMBIA · PI NGALAMIKA, OWEN · 2018 to 2023
$721k
FIC NIH HHS D43 TW010354FIC NIH HHS K43 TW011095FIC NIH HHS K43 TW011418NCI NIH HHS R01 CA228178NCI NIH HHS U54 CA221204
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) virus is the cause of coronavirus disease 2019 (COVID-19). It has caused millions of infections and deaths globally over a 2-year period. Some populations including those living with HIV and/or cancer are reported to be at a higher risk of infection and severe disease. HIV infection leads to a depletion of CD4

Indexed as

COVID-19HIV InfectionsSarcoma, KaposiAntibodies, ViralHumansImmunity, CellularSARS-CoV-2T-LymphocytesZambiaAntibodies, Viral

Identifiers

PMID35935575
PMCPMC9352483
OpenAlexW4288719554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.